NCT00916604View on ClinicalTrials.gov

To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2009

Study Completion Date

October 31, 2009

Conditions
Type 2 Diabetes
Interventions
DRUG

AZD1656

Three increasing dose-steps with oral suspension, 8 days treatment

DRUG

Placebo

Placebo oral suspension, 8 days treatment

Trial Locations (2)

Unknown

Research Site, Fukuoka

Research Site, Tokyo

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY